Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05278039
Other study ID # R01CA262502
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date May 19, 2022
Est. completion date July 1, 2026

Study information

Verified date June 2024
Source Northwestern University
Contact Bonnie Martin-Harris, PhD
Phone 847-467-7447
Email scsc@northwestern.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Head and neck cancers have escalated to epidemic levels in the United States, and survivors are suffering from life-long, devastating swallowing disorders with limited therapeutic options. This clinical trial investigates a novel swallowing treatment that trains initiation of swallowing during the expiratory phase of respiration to improve swallowing safety and efficiency.


Description:

Head and neck cancers (HNC) have increased to epidemic levels in the United States. Despite good response to cancer treatment, survivors are suffering life-long toxicities that result in swallowing problems (dysphagia). Treatment options for dysphagia after HNC are extremely limited, focus on swallowing movements alone, and do not consider the importance of respiratory-swallow phase patterning. Prior evidence has demonstrated that when aberrant respiratory-swallow phase patterning is present (initiation of swallowing during inspiration) in patients with HNC, there is a higher occurrence of swallowing impairments, increased residue, and airway invasion. Further, it has been well established that the expiratory limb of the respiratory cycle provides a biomechanically advantageous set point in which to initiate safe and efficient swallowing. This randomized, controlled, Phase II clinical trial examines if respiratory-swallow phase training improves airway protection and swallowing efficiency in HNC survivors who are three or more months post-completion of first-line cancer treatment. The primary goal (Aim 1) is to determine if respiratory-swallow phase training results in increased frequency (%) of swallows initiated during expiration and improved swallowing safety. The secondary goal (Aim 2) is to examine the impact of respiratory-swallow phase training on the frequency of swallows initiated during expiration in wakeful, naturalistic swallowing environments, including eating and drinking. The investigators will recruit 88 HNC survivors with dysphagia, impaired respiratory-swallow phase patterning, and airway compromise. The investigators will deliver therapy remotely using a telehealth platform and an innovative wearable sensor that provides real-time visual feedback of respiratory-swallow movements. Endpoints will be measured from synchronized videofluoroscopic and respiratory-swallow sensor recordings at baseline, within 1-week post-treatment, and 1-month and 3-months post-treatment.


Recruitment information / eligibility

Status Recruiting
Enrollment 88
Est. completion date July 1, 2026
Est. primary completion date July 1, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Diagnosis of primary head and neck cancer - Three or more months post-completion of first-line cancer treatment - English speaking - Functional/corrected visual and hearing acuity - No current alcohol or other drug abuse - Without very severe (forced expiratory volume; FEV) 1 <30% predicted) stage Chronic Obstructive Pulmonary Disease (COPD) based on Pulmonary Function Testing (PFT) - No skin allergy to the medical-grade sensor adhesive - Tolerate wearing the sensor for at least 10 hours/day - Tolerate some liquid oral intake on a routine basis - Normal dexterity to self-administer liquids via teaspoon - Initiation of swallowing during inspiratory phase of respiration on =20% of swallows - Penetration Aspiration Scale (PAS) score =3 or impairment on at least one MBSImP OI score (laryngeal vestibular closure =1, tongue base retraction =2, or pharyngeal residue =2) on at least one swallow during lateral view of MBSS - A PAS score of =6 on at least one liquid consistency without the use of a compensatory strategy or swallow maneuver Exclusion Criteria: - Persistent or recurrent cancer at the time of enrollment - Known allergy to contrast materials or liquids used during the MBSS or training - Known allergy to sensor adhesive - Unable to demonstrate competency with the user-friendly technology - Diagnosis of neurological disorders - Indwelling tracheostomy tube - Nasogastric (NG) feeding tube - History of aspiration pneumonia within the past 12 months - Unable to self-administer liquid boluses - Unable to swallow some liquids without a maneuver - Likely or currently pregnant

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Respiratory-Swallow Phase Training
Participants will complete 6 respiratory-swallow phase training sessions that will last approximately one hour.
Other:
Swallow Practice
Participants will complete 6 "swallow practice" sessions that will last approximately one hour.

Locations

Country Name City State
United States Northwestern Memorial Hospital Chicago Illinois
United States Northwestern University Evanston Illinois

Sponsors (2)

Lead Sponsor Collaborator
Northwestern University Northwestern Memorial Hospital

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Change in M.D. Anderson Dysphagia Inventory (MDADI) scores Evaluates the impact of dysphagia on the quality of life of patients with head and neck cancer Change from baseline to 1-week post-treatment, 1-month post-treatment, and 3-months post treatment. Scores range from 20 to 100 and higher scores indicate worse outcome.
Primary Change in frequency (%) of swallows initiated during expiration Determines percent (frequency) of the target (expiratory phase) for each swallow. Change from baseline to 1-week post-treatment and 2-4-6-8-10-12-weeks post-treatment.
Primary Change in Penetration-Aspiration Scale scores Measures presence, depth and reaction to penetration and aspiration. Change from baseline to 1-week post-treatment, 1-month post-treatment, and 3-months post treatment. Scores range from 1-8 and higher scores indicate worse outcome.
Secondary Change in Normalized Residue Ratio Scale scores Quantifies pharyngeal space residue obtained in the lateral view during Modified Barium Swallow Study (MBSS) Change from baseline to 1-week post-treatment, 1-month post-treatment, and 3-months post treatment. Scores range from 0 to 100% and higher scores indicate worse outcome.
Secondary Change in Modified Barium Swallow Impairment Profile (MBSImP) scores Measures physiologic swallowing impairment from observations of MBSS recordings Change from baseline to 1-week post-treatment, 1-month post-treatment, and 3-months post treatment. Oral Total scores range from 0-22 and Pharyngeal Total scores range from 0-26 and higher values indicate worse outcome.
See also
  Status Clinical Trial Phase
Recruiting NCT05808920 - The RESCUE Study: Survival and Functional Outcomes Following Salvage Surgery for RESidual or reCurrent sqUamous cEll Carcinoma of the Head and Neck
Completed NCT02526017 - Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers Phase 1
Active, not recruiting NCT05060432 - Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT03997643 - Preservation of Swallowing in Respected Oral Cavity Squamous Cell Carcinoma: Examining Radiation Volume Effects (PRESERVE): A Randomized Trial Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Recruiting NCT04700475 - Effect of Low Level Laser Therapy on Prevention of Radiotherapy Induced Xerostomia in Cancer Patients. N/A
Withdrawn NCT04058145 - AMD3100 Plus Pembrolizumab in Immune Checkpoint Blockade Refractory Head and Neck Squamous Cell Carcinoma Phase 2
Completed NCT02572869 - Functional and Aesthetic Outcomes After Mandible Reconstruction With Fibula Osteomyocutaneous Free Flaps
Active, not recruiting NCT04474470 - A Study to Evaluate NT219 Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer Phase 1/Phase 2
Withdrawn NCT05073809 - Photoacoustic Imaging of Head and Neck Tumours
Active, not recruiting NCT04383210 - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Phase 2
Active, not recruiting NCT03651570 - Randomized Controlled Trial of a E-intervention to Help Patients Newly Diagnosed With Cancer Cope Better: Pilot Study N/A
Recruiting NCT04930432 - Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors Phase 1/Phase 2
Recruiting NCT06016699 - Immunological Function After Radiation With Either Proton or Photon Therapy
Terminated NCT03843554 - Commensal Oral Microbiota in Head and Neck Cancer N/A
Recruiting NCT05915572 - Mulligan Technique on Shoulder Dysfunction N/A
Completed NCT05897983 - Tens and Rocabado Exercises on TMJ Dysfunction N/A
Not yet recruiting NCT06289049 - Heavy Strength Training in Head and Neck Cancer Survivors Phase 2
Withdrawn NCT05263648 - Virtual Reality Software to Reduce Stress in Cancer Patients N/A
Withdrawn NCT03238638 - A Study of Epacadostat + Pembrolizumab in Head and Neck Cancer Patients, Who Failed Prior PD-1/PD-L1 Therapy Phase 2